Abstract:Background and objectives: Cognitive decline rates in Alzheimer disease (AD) vary greatly. Disease-modifying treatments may alter cognitive decline trajectories, rendering their prediction increasingly relevant. We aimed to construct clinically applicable prediction models of cognitive decline in amyloid-positive patients with mild cognitive impairment (MCI) or mild dementia. Methods: From the Amsterdam Dementia Cohort, we selected amyloid-positive participants with MCI or mild dementia and at least 2 longitudinal Mini-Mental State Examination (MMSE) measurements. Amyloid positivity was based on CSF AD biomarker concentrations or amyloid PET. We used linear mixed modeling to predict MMSE over time, describing trajectories using a cubic time curve and interactions between linear time and the baseline predictors age, sex, baseline MMSE, APOE ε4 dose, CSF β-amyloid (Aβ) 1-42 and pTau, and MRI total brain and hippocampal volume. Backward selection was used to reduce model complexity. These models can predict MMSE over follow-up or the time to an MMSE value. MCI and mild dementia were modeled separately. Internal 5-fold cross-validation was performed to calculate the explained variance (R2). Results: In total, 961 participants were included (age 65 ± 7 years, 49% female), 310 had MCI (MMSE 26 ± 2) and 651 had mild dementia (MMSE 22 ± 4), with 4 ± 2 measurements over 2 (interquartile range 1-4) years. Cognitive decline rates increased over time for both MCI and mild dementia (model comparisons linear vs squared vs cubic time fit; p < 0.05 favoring a cubic fit). For MCI, backward selection retained age, sex, and CSF Aβ1-42 and pTau concentrations as time-varying effects altering the MMSE trajectory. For mild dementia, retained time-varying effects were Aβ1-42, age, APOE ε4, and baseline MMSE. R2 was 0.15 for the MCI model and 0.26 for mild dementia in internal cross-validation. A hypothetical patient with MCI, baseline MMSE 28, and CSF Aβ1-42 of 925 pg/mL was predicted to reach an MMSE of 20 after 6.0 years (95% CI 5.4-6.7) and after 8.6 years with a hypothetical treatment reducing decline by 30%. Discussion: We constructed models for MCI and mild dementia that predict MMSE over time. These models could inform patients about their potential cognitive trajectory and the remaining uncertainty and aid in conversations about individualized potential treatment effects.

Prediction of cognitive decline for enrichment of Alzheimer's disease clinical trials

Automatic prediction of cognitive and functional decline can significantly decrease the number of subjects required for clinical trials in early Alzheimer's disease

A Machine Learning Approach to Predict Cognitive Decline in Alzheimer's Disease Clinical Trials

Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer's Disease

Individualized and Biomarker-Based Prognosis of Longitudinal Cognitive Decline in Early Symptomatic Alzheimer's Disease

Predicting Cognitive Declines Using Longitudinally Enriched Representations For Imaging Biomarkers

A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer's disease

Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia

Improving clinical efficiency in screening for cognitive impairment due to Alzheimer's

PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS

Predictors of the rate of cognitive decline in older adults using machine learning

The relative efficiency of time-to-progression and continuous measures of cognition in pre-symptomatic Alzheimer's

Towards Multimodal Longitudinal Analysis for Predicting Cognitive Decline Using Neuroimaging Biomarkers, Cognitive Assessments, and Demographic Data

Simulation of virtual cohorts increases predictive accuracy of cognitive decline in MCI subjects

Predicting Cognitive Decline for Non-Demented Adults with High Burden of Tau Pathology, Independent of Amyloid Status

Biomarkers for predicting cognitive decline in those with normal cognition.

Machine Learning Approach for Improved Longitudinal Prediction of Progression from Mild Cognitive Impairment to Alzheimer’s Disease

Crowdsourced Estimation of Cognitive Decline and Resilience in Alzheimer's Disease

A Machine Learning Approach for Predicting Deterioration in Alzheimer's Disease

Predictive Modeling Of Alzheimer's Disease Prognosis Using Anatomical & Diffusion MRI

Learning semi-supervised enrichment of longitudinal imaging-genetic data for improved prediction of cognitive decline